Back to top
more

Bristol Myers Squibb (BMY)

(Real Time Quote from BATS)

$55.30 USD

55.30
7,657,067

+0.98 (1.80%)

Updated Nov 4, 2024 03:55 PM ET

After-Market: $55.46 +0.16 (0.29%) 4:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sweta Killa headshot

Healthcare ETFs to Watch As Q4 Earnings Unfold

by Sweta Killa

With earnings surprises well in the cards, the healthcare sector is expected to witness earnings growth of 3% in the fourth quarter, suggesting some upside for healthcare ETFs.

    Bristol-Myers (BMY) Reports Data from CheckMate-142 Study

    by Zacks Equity Research

    Bristol-Myers (BMY) announces new data from a cohort of the phase II CheckMate -142 study evaluating Opdivo (nivolumab) and Yervoy (ipilimumab).

      Arpita Dutt headshot

      Pharma Stock Roundup: Merck's Keytruda Shines in Study, Priority Review for Kymriah Label Expansion

      by Arpita Dutt

      Focus this week was on Merck's (MRK) data on Keytruda as well as Novartis's updates on Kymriah and its biosimilar efforts.

        Exelixis, Ipsen Report Positive Results on Lead Cancer Drug

        by Zacks Equity Research

        Exelixis (EXEL) and Ipsen announce detailed results from the late stage study of lead drug Cabometyx in patients with previously treated advanced HCC.

          Arpita Dutt headshot

          Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference

          by Arpita Dutt

          Focus this week was on pipeline updates provided by several companies including Pfizer (PFE) at a healthcare conference while Novo Nordisk's bid to acquire Ablynx also made news.

            Arpita Dutt headshot

            Key Takeaways from Pfizer & 3 Other Drug Stocks at Healthcare Conference

            by Arpita Dutt

            Here is a look at key takeaways from presentations made by four major pharma and biotech stocks including Pfizer (PFE) at the annual J.P. Morgan healthcare conference.

              Exelixis Amends Cabozantinib-Tecentriq Phase Ib Trial

              by Zacks Equity Research

              Exelixis, Inc. (EXEL) announced an amendment to the protocol for the phase Ib trial of cabozantinib combined with Tecentriq whereby there will be four new expansion cohorts to the trial.

                Seattle Genetics' Adcetris sBLA Gets FDA Priority Review

                by Zacks Equity Research

                Seattle Genetics' supplemental Biologics License Application for the label expansion of its lymphoma drug, Adcetris, was accepted by the FDA and granted priority review.

                  4 Reasons to Include Celldex (CLDX) Stock in Your Portfolio

                  by Zacks Equity Research

                  Celldex stock has been performing well for the last six months and the momentum is likely to continue in the near term.

                    Arpita Dutt headshot

                    Pharma Stock Roundup: Roche, MNK Announce Acquisition Agreements, Regulatory Updates from Novartis

                    by Arpita Dutt

                    Although it's been a relatively slow week, two acquisition deals were announced with Roche (RHHBY) saying it will acquire Ignyta while Mallinckrodt will buy Sucampo.

                      Clovis Up More Than 50% in 2017: What's Driving the Stock?

                      by Zacks Equity Research

                      Clovis Oncology (CLVS) stock is rapidly gaining momentum. The company's only approved drug Rubraca is off to an impressive start and is nearing label expansion approval.

                        Will Exelixis (EXEL) be Able to Carry '17 Momentum in 2018?

                        by Zacks Equity Research

                        Exelixis (EXEL) had a phenomenal run in 2017 driven by sales of Cabometyx and we expect the momentum to continue in 2018 on the back of the label expansion of the drug.

                          Merck's Diabetes Drugs Get FDA Nod as Adjunct Therapies

                          by Zacks Equity Research

                          Merck's (MRK) three diabetes drugs get FDA approval as adjunct treatment to diet and exercise to improve glycemic control in patients with diabetes mellitus.

                            Portola's (PTLA) AndexXa BLA Review Period Extended by FDA

                            by Zacks Equity Research

                            The FDA extends the review period of Portola's (PTLA) biologics license application for AndexXa by 90 days. Its response is now deferred to May 4, 2018 instead of the earlier Feb 3 deadline.

                              Cancer Space Update: FDA Approves Label Expansion of 4 Drugs

                              by Zacks Equity Research

                              The FDA has approved label expansion of four different drugs from Roche, Exelixis, Pfizer and Bristol-Myers. However, Celgene faced a setback as Revlimid failed in a phase III study.

                                Arpita Dutt headshot

                                Pharma Stock Roundup: Aerie's Rhopressa Approved, Label Expansion for BMY, Pfizer Drugs

                                by Arpita Dutt

                                This week's pharma sector highlights include the FDA approval of Aerie's (AERI) Rhopressa as well as the label expansion of Pfizer's Bosulif and Bristol-Myers's Opdivo.

                                  Roche's Perjeta Gets FDA Nod for Post Surgery Breast Cancer

                                  by Zacks Equity Research

                                  Roche's (RHHBY) Perjeta in combination with Herceptin and chemotherapy (the Perjeta-based regimen), gets FDA nod for adjuvant (after surgery) treatment of HER2-positive early breast cancer at high risk of recurrence

                                    LabCorp (LH) at a 52-Week High: What's Driving the Stock?

                                    by Zacks Equity Research

                                    LabCorp (LH) banks on Chiltern International Group's buyout. An upbeat guidance boosts investors' confidence.

                                      What's Happening in Advanced Renal Cell Carcinoma Space?

                                      by Zacks Equity Research

                                      The advanced renal cell carcinoma space is back in focus as the FDA approved Cabometyx for treatment-naive patients. Investors will keep an eye on other combination therapies being evaluated for the treatment of advanced RCC,

                                        Exelixis' Cabometyx Gets FDA Nod for First-Line Kidney Cancer

                                        by Zacks Equity Research

                                        Exelixis (EXEL) received a significant boost with the approval of label expansion of lead drug Cabometyx for first-line kidney cancer.

                                          AstraZeneca's Tagrisso Label Expansion Filing Accepted by FDA

                                          by Zacks Equity Research

                                          AstraZeneca's (AZN) regulatory application for label expansion of Tagrisso to include treatment of NSCLC with EGFR mutation in first-line setting has been accepted by the FDA.

                                            Bristol-Myers Yervoy Gets Positive CHMP Opinion for Melanoma

                                            by Zacks Equity Research

                                            Bristol-Myers Squibb Company (BMY) immuno-oncology drug Yervoy gets positive opinion from the CHMP of the European Medicines Agency for the treatment of pediatric patients of 12 years and older with unresectable or metastatic melanoma.

                                              Bristol-Myers' Opdivo/Yervoy sBLA for RCC Accepted by FDA

                                              by Zacks Equity Research

                                              Bristol-Myers (BMY) supplemental Biologics License Application (sBLA) for Opdivo and Yervoy combination for the treatment of intermediate- and poor-risk patients with advanced renal cell carcinoma was accepted by the FDA.

                                                Arpita Dutt headshot

                                                Pharma Stock Roundup: Teva Announces Major Job Cuts, Lilly Provides 2018 Outlook

                                                by Arpita Dutt

                                                This week's pharma sector highlights include ASH data, Teva's restructuring announcement and Lilly's (LLY) 2018 outlook.

                                                  Bristol-Myers (BMY) Reports Positive Data on Leukemia Drug

                                                  by Zacks Equity Research

                                                  Bristol-Myers Squibb Company (BMY) announced positive data from an ongoing phase II study on leukemia drug Sprycel in addition to a chemotherapy regimen modelled on a Berlin-Frankfurt-Munster high-risk backbone for two years.